With the remarkable new advances in the treatment of renal cell carcinoma combined with patients advocating for their own care it is critical to provide patients, families, and their healthcare providers with convenient access to state of the art information summarizing the evolving treatment strategies and clinical research in this disease
Chicago, IL, and Duarte, CA (PRWEB) May 8, 2008
Kidney Cancer Association and City of Hope Comprehensive Cancer Center announced today it has launched a new renal cell carcinoma (RCC) health information portal, http://www.RCCTrends.com to inform healthcare providers and patients about new advances for the treatment of RCC. The web site provides access to information that tracks the progress of clinical research and evolving treatment strategies for patients with RCC and offers a self study, web-based, certified continuing medical education activity to healthcare providers. The activity is designated for 5 AMA Physicians' Recognition Award™ credits and is supported by an educational grant from Wyeth.
"With the remarkable new advances in the treatment of renal cell carcinoma combined with patients advocating for their own care it is critical to provide patients, families, and their healthcare providers with convenient access to state of the art information summarizing the evolving treatment strategies and clinical research in this disease," said Robert A. Figlin, MD, Professor and Chair, Medical Oncology and Therapeutics Research, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
About Renal Cell Carcinoma
Kidney cancer accounts for 3.5% of all cancers in the US and represents the seventh most common cancer in men and ninth in women. Prognosis for patients with metastatic RCC is poor with a 5-year survival rate of 9.5%. Standard treatment offers limited benefit however new understanding about the biologic basis of renal oncogenesis has lead researchers to develop new targeted therapy for advanced RCC.
RCC has been one of the more drug-resistant malignancies. An interest in the identification of specific targets for therapy has been underway for the last century and has recently received enormous attention with the knowledge expansion of molecular targets. Molecular complexities of both the disease and the treatment are resulting in a rapidly evolving environment in the treatment of kidney cancer.
About the City of Hope
The City of Hope located in Duarte California is one of 39 NCI-designated Cancer Centers in the United States and a founding member of the National Comprehensive Cancer Network. More than 300 physicians and scientists and over 2,500 employees work to find the causes of and cures for cancer and other life-threatening diseases, including diabetes and HIV/AIDS. The City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians with over 300 accredited programs throughout the year.
About the Kidney Cancer Association
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals. We fund, promote, and collaborate with the National Cancer Institute (NCI), American Society for Clinical Oncology (ASCO), American Urologic Association (AUA), and other institutions on research projects. We educate families and physicians, and serve as an advocate on behalf of patients at the state and federal levels.